CARDIOVASCULAR EVENTS WITH DE NOVO USE OF EVEROLIMUS IN HEART TRANSPLANT RECIPIENTS

被引：0
|
作者：
Potena, Luciano [1 ]
Schulz, Uwe
Bara, Christoph [2 ]
Arizon Del Prado, Jose M. [3 ]
Balfour, Alison [4 ]
Kohler, Sven [4 ]
Lopez, Patricia M. [4 ]
Epailly, Eric [5 ]
机构：
[1] Univ Bologna, Acad Hosp S Orsola Malpighi, Bologna, Italy
[2] Hannover Med Sch, Hannover, Germany
[3] HURS, Cordoba, Spain
[4] Novartis Pharma AG, Basel, Switzerland
[5] Chirurg Cardiaque Hop Univ Strasbourg, Strasbourg, France
来源：
TRANSPLANT INTERNATIONAL | 2013年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：46 / 46
页数：1
相关论文
共 50 条
  • [21] Everolimus and cyclosporine reduction in de novo heart transplant recipients transplants:: Impact on wound healing
    Zuckermann, Andreas
    Wang, Shoei-Sheng
    Keogh, Anne M.
    Ross, Heather
    Frigerio, Maria
    Eisen, Howard J.
    Bara, Christoph
    Laufer, Guenther
    Cotrufo, Maurizio
    TRANSPLANT INTERNATIONAL, 2007, 20 : 95 - 95
  • [22] COMPARISON OF WOUND HEALING EVENTS AND EFFUSIONS IN DE NOVO HEART TRANSPLANT RECIPIENTS TREATED WITH EVEROLIMUS VS. MMF BASED REGIMENS
    Hirt, S.
    Eisen, H.
    Bara, C.
    Costard-Jaeckle, A.
    Schulz, U.
    Lopez, P.
    Zuckermann, A.
    Lehmkuhl, H. B.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 50 - 50
  • [23] Safety of Early Everolimus in De Novo Heart Transplant Recipients: Interim Analysis of the Randomized Study EVERHEART
    Potena, L.
    Barberini, F.
    Boffini, M.
    Amarelli, C.
    Pellegrini, C.
    Livi, U.
    Masciocco, G.
    Faggian, G.
    Gerosa, G.
    Lilla, P.
    Marraudino, N.
    Porcu, M.
    Guarisco, R.
    Maccherini, M.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2013, 32 (04): : S136 - S136
  • [24] Exposure to CsA, and not to everolimus, is associated with impaired renal function in de novo heart transplant recipients.
    Varnous, Shaida
    Livi, Ugolino
    Poncelet, Alain
    Delgado, Juan
    Vermes, Emmanuelle
    Li, Yulan
    Arizon, Jose
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 346 - 346
  • [25] Everolimus immunosuppression in de novo heart transplant recipients: What does the evidence tell us now?
    Zuckermann, Andreas
    Wang, Shoei-Shen
    Epailly, Eric
    Barten, Markus J.
    Sigurdardottir, Vilborg
    Segovia, Javier
    Varnous, Shaida
    Turazza, Fabio M.
    Potena, Luciano
    Lehmkuhl, Hans B.
    TRANSPLANTATION REVIEWS, 2013, 27 (03) : 76 - 84
  • [26] Everolimus Treatment Reduces the Need for Anti-CMV Prophylaxis in De Novo Heart Transplant Recipients
    Potena, L.
    Bianchi, I. G.
    D'Agostino, C.
    Abate, D.
    Magnani, G.
    Chiereghin, A.
    Grigioni, F.
    Gambino, A.
    Toscano, G.
    Sgarabotto, D.
    Gerosa, G.
    Branzi, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (04): : S64 - S64
  • [27] Relationship Between Clinical Events and Everolimus Exposure at 12 Months in De Novo Renal Transplant Recipients.
    Shihab, F.
    Qazi, Y.
    Mulgaonkar, S.
    McCague, K.
    Patel, D.
    Peddi, V.
    Shaffer, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 217 - 217
  • [28] De novo major cardiovascular events in kidney transplant recipients: a comparative matched cohort study
    Kim, Ji Eun
    Park, Jina
    Park, Sehoon
    Yu, Mi-Yeon
    Ha Baek, Seon
    Park, Sang Hyun
    Han, Kyungdo
    Kim, Yong Chul
    Kim, Dong Ki
    Oh, Kook-Hwan
    Joo, Kwon Wook
    Kim, Yon Su
    Lee, Hajeong
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (02) : 499 - 506
  • [29] ADVERSE EVENTS ASSOCIATED WITH mTOR INHIBITION: RESULTS FROM THE A2310 STUDY COMPARING EVEROLIMUS AND MMF IN DE NOVO HEART TRANSPLANT RECIPIENTS
    Poncelet, A.
    Musumeci, F.
    Fuchs, U.
    Mattei, M. F.
    Dong, G.
    Lopez, P.
    Hirt, S.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 58 - 58
  • [30] PHARMACOKINETICS OF EVEROLIMUS WHEN COMBINED WITH TACROLIMUS IN DE NOVO RENAL TRANSPLANT RECIPIENTS
    Rostaing, L.
    Pascual, J.
    Machein, U.
    Kovarik, J. M.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 253 - 253
12345